Literature DB >> 17219969

Cyclin E expression and chemotherapeutic sensitivity in breast cancer cells.

Jianying Chen1, Guobin Wang.   

Abstract

The effects of the cyclin E expression levels on chemotherapeutic sensitivity of breast cancer cell line were explored. After the cyclin E expression was knockdown in MDA-MB-435 by RNA interference, FACS analysis and SA-beta-gal staining were used to evaluate the response sensitivity of breast cancer cells to DNA damage drugs (adriamycin, etc.). Adriamycin could induce G1 arrest in cyclin E knockdown MDA-MB-435 breast cell line and increase the percentage of cell senescence in cyclin E knockdown MDA-MB-435 cells. It was suggested that cyclin E knockdown could increase the chemotherapeutic sensitivity of breast cancer cells to DNA damage drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17219969     DOI: 10.1007/s11596-006-0521-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  5 in total

Review 1.  Cyclin E as a prognostic and predictive marker in breast cancer.

Authors:  Kelly K Hunt; Khandan Keyomarsi
Journal:  Semin Cancer Biol       Date:  2005-08       Impact factor: 15.707

2.  DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

Authors:  Robert H te Poele; Andrei L Okorokov; Lesley Jardine; Jeffrey Cummings; Simon P Joel
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

Review 3.  Cellular senescence as a tumor-suppressor mechanism.

Authors:  J Campisi
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

4.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

Authors:  G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

5.  Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma.

Authors:  Kaiyi Li; Shiaw-Yih Lin; F Charles Brunicardi; Philip Seu
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

  5 in total
  1 in total

1.  Reinforcing targeted therapeutics with phenotypic stability factors.

Authors:  Paul Yaswen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.